Tumor-Infiltrating Mast Cells in Angiosarcoma Correlate With Immuno-Oncology Pathways and Adverse Clinical Outcomes

被引:5
|
作者
Tai, Sarah Beishan [1 ,2 ]
Lee, Elizabeth Chun Yong [2 ]
Lim, Boon Yee [2 ]
Kannan, Bavani [2 ]
Lee, Jing Yi [2 ]
Guo, Zexi [2 ]
Ko, Tun Kiat [2 ]
Ng, Cedric Chuan -Young [2 ]
Teh, Bin Tean [3 ,4 ]
Chan, Jason Yongsheng [2 ,4 ,5 ]
机构
[1] Singapore Gen Hosp, Dept Nucl Med & Mol Imaging, Singapore, Singapore
[2] Natl Canc Ctr, Canc Discovery Hub, Singapore, Singapore
[3] Natl Canc Ctr, Lab Canc Epigenome, Singapore, Singapore
[4] Duke NUS Med Sch, Singapore, Singapore
[5] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
基金
英国医学研究理事会;
关键词
sarcoma; next-generation sequencing; immunotherapy; mast cells; immuno-oncology; ENDOTHELIAL GROWTH-FACTOR; CANCER; PROGNOSIS; LYMPHOMA; SURVIVAL;
D O I
10.1016/j.labinv.2024.100323
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Recent studies have described several molecular subtypes and deregulation of immuno-oncologic signaling pathways in angiosarcoma. Interestingly, mast cells were enriched in subsets of angiosarcoma, although their significance remains unknown. In this study, we aim to verify this observation using immunohistochemistry (H scores) and NanoString transcriptomic profiling and explore the association between mast cells with clinical and biological features. In the study cohort (N = 60), H scores showed a significant moderate correlation with NanoString mast cell scores (r = 0.525; P < .001). Both H score and NanoString mast cell scores showed a significant positive correlation (P < .05) with head and neck location, nonepithelioid morphology, and lower tumor grade. Mast cell enrichment significantly correlated with higher NanoString regulatory T-cell scores (H score, r = 0.32; P = .01; NanoString mast cell score, r = 0.27; P = .04). NanoString mast cell scores positively correlated with signaling pathways relating to antigen presentation (r = 0.264; P = .0414) and negatively correlated with apoptosis (r = -0.366; P = .0040), DNA damage repair (r = -0.348; P = .0064), and cell proliferation (r = -0.542; P < .001). Interestingly, in the metastatic setting, patients with mast cell-enriched angiosarcoma showed poorer progressionfree survival (median, 0.2 vs 0.4 years; hazard ratio = 3.05; P = .0489) along with a trend toward worse overall survival (median, 0.2 vs 0.6 years; hazard ratio, 2.86; P = .0574) compared with patients with mast cell-poor angiosarcoma. In conclusion, we demonstrated the presence of mast cells in human angiosarcoma and provided initial evidence of their potential clinical and biological significance. Future research will be required to elucidate their specific roles and mechanisms, which may uncover novel avenues for therapeutic intervention. (c) 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Prognostic value of tumor-infiltrating immune cells in clinical early-stage oral squamous cell carcinoma
    Huang, Zhengxian
    Lu, Yanwen
    Wang, Wenjin
    Xie, Nan
    Yi, Chen
    Xiong, Gan
    Xu, Xiuyun
    Zhang, Ming
    Wang, Cheng
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2023, 52 (05) : 372 - 380
  • [32] Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma
    Plesca, Ioana
    Benesova, Iva
    Beer, Carolin
    Sommer, Ulrich
    Mueller, Luise
    Wehner, Rebekka
    Heiduk, Max
    Aust, Daniela
    Baretton, Gustavo
    Bachmann, Michael P.
    Feldmann, Anja
    Weitz, Juergen
    Seifert, Lena
    Seifert, Adrian M.
    Schmitz, Marc
    CANCERS, 2022, 14 (05)
  • [33] Clinical impact of tumor-infiltrating CD45RO+ memory T cells on human gastric cancer
    Wakatsuki, Kohei
    Sho, Masayuki
    Yamato, Ichiro
    Takayama, Tomoyoshi
    Matsumoto, Sohei
    Tanaka, Tetsuya
    Migita, Kazuhiro
    Ito, Masahiro
    Hotta, Kiyohiko
    Nakajima, Yoshiyuki
    ONCOLOGY REPORTS, 2013, 29 (05) : 1756 - 1762
  • [34] Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy
    Toyoda, Shingo
    Fukuokaya, Wataru
    Mori, Keiichiro
    Kawada, Tatsushi
    Katayama, Satoshi
    Nishimura, Shingo
    Maenosono, Ryoichi
    Tsujino, Takuya
    Adachi, Takahiro
    Hirasawa, Yosuke
    Saruta, Masanobu
    Komura, Kazumasa
    Nukaya, Takuhisa
    Yanagisawa, Takafumi
    Takahara, Kiyoshi
    Hashimoto, Takeshi
    Azuma, Haruhito
    Ohno, Yoshio
    Shiroki, Ryoichi
    Araki, Motoo
    Kimura, Takahiro
    Fujita, Kazutoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (12) : 1336 - 1342
  • [35] Tumor-infiltrating T-cells: important players in clinical outcome of advanced melanoma patients
    Tjin, Esther P. M.
    Luiten, Rosalie M.
    ONCOIMMUNOLOGY, 2014, 3 (09) : 1 - 3
  • [36] Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
    Dieci, Maria Vittoria
    Radosevic-Robin, Nina
    Fineberg, Susan
    van den Eynden, Gert
    Ternes, Nils
    Penault-Llorca, Frederique
    Pruneri, Giancarlo
    D'Alfonso, Timothy M.
    Demaria, Sandra
    Castaneda, Carlos
    Sanchez, Joselyn
    Badve, Sunil
    Michiels, Stefan
    Bossuyt, Veerle
    Rojo, Federico
    Singh, Baljit
    Nielsen, Torsten
    Viale, Giuseppe
    Kim, Seong-Rim
    Hewitt, Stephen
    Wienert, Stephan
    Loibl, Sybille
    Rimm, David
    Symmans, Fraser
    Denkert, Carsten
    Adams, Sylvia
    Loi, Sherene
    Salgado, Roberto
    SEMINARS IN CANCER BIOLOGY, 2018, 52 : 16 - 25
  • [37] PD-L1 Expression in Endocervical Adenocarcinoma Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes
    Rivera-Colon, Glorimar
    Chen, Hao
    Molberg, Kyle
    Niu, Shuang
    Strickland, Amanda L.
    Castrillon, Diego H.
    Carrick, Kelley
    Gwin, Katja
    Lea, Jayanthi
    Zheng, Wenxin
    Lucas, Elena
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (06) : 742 - 752
  • [38] Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
    Brase, Jan C.
    Walter, Robert F. H.
    Savchenko, Alexander
    Gusenleitner, Daniel
    Garrett, James
    Schimming, Tobias
    Varaljai, Renata
    Castelletti, Deborah
    Kim, Ju
    Dakappagari, Naveen
    Schultz, Ken
    Robert, Caroline
    Long, Georgina V.
    Nathan, Paul D.
    Ribas, Antoni
    Flaherty, Keith T.
    Karaszewska, Boguslawa
    Schachter, Jacob
    Sucker, Antje
    Schmid, Kurt W.
    Zimmer, Lisa
    Livingstone, Elisabeth
    Gasal, Eduard
    Schadendorf, Dirk
    Roesch, Alexander
    CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4500 - 4510
  • [39] Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients
    Xiaobo Bo
    Jie Wang
    Tao Suo
    Xiaoling Ni
    Han Liu
    Sheng Shen
    Min Li
    Yueqi Wang
    Houbao Liu
    Jiejie Xu
    BMC Cancer, 18
  • [40] Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma
    Pillai, Manon
    Jiang, Yizhou
    Lorigan, Paul C.
    Thistlethwaite, Fiona C.
    Thomas, Martine
    Kirillova, Natalia
    Bridgeman, John S.
    Kueberuwa, Gray
    Biswas, Sunetra
    Velazquez, Peter
    Chonzi, David
    Guest, Ryan D.
    Roberts, Zachary J.
    Hawkins, Robert E.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (08): : 3967 - +